Evaluating warfarin management by pharmacists in a community teaching hospital.

MedStar author(s):
Citation: Consult Pharm. 29(2):95-103, 2014 Feb.Consultant Pharmacist. 29(2):95-103, 2014 Feb.PMID: 24513419Institution: MedStar Union Memorial HospitalDepartment: PharmacyForm of publication: Journal ArticleMedline article type(s): Comparative Study | Journal ArticleSubject headings: *Anticoagulants/tu [Therapeutic Use] | *Drug Monitoring/mt [Methods] | *Pharmacists/og [Organization & Administration] | *Warfarin/tu [Therapeutic Use] | Aged | Aged, 80 and over | Anticoagulants/ae [Adverse Effects] | Cohort Studies | Drug Interactions | Female | Hemorrhage/ci [Chemically Induced] | Hemorrhage/ep [Epidemiology] | Hospitals, Teaching | Humans | International Normalized Ratio | Male | Middle Aged | Pharmacy Service, Hospital/og [Organization & Administration] | Physicians/og [Organization & Administration] | Retrospective Studies | Time Factors | Warfarin/ae [Adverse Effects]Year: 2014ISSN:
  • 0888-5109
Name of journal: The Consultant pharmacist : the journal of the American Society of Consultant PharmacistsAbstract: CONCLUSION: Similar results were observed for pharmacist-managed and physician-managed patients for INR monitoring and outcome rates. However, the pharmacist-managed patients demonstrated a lower incidence of supratherapeutic INRs and significantly more time within goal.DESIGN: Retrospective cohort study.INTERVENTIONS: The electronic medical record was reviewed for demographics, warfarin indication and goal range, international normalized ratios (INRs), albumin, drug-drug interactions, bleeding, and thrombotic rates.MAIN OUTCOME MEASURES: Primary endpoints included mean time to therapeutic INR, mean time within goal, frequency of supratherapeutic INRs, bleeding, thrombotic rates, and mean INR on discharge.OBJECTIVE: The purpose of this study was to evaluate warfarin management by pharmacists compared with physicians through an inpatient anticoagulation management service (AMS).PATIENTS, PARTICIPANTS: Patients were randomly selected from the Inpatient AMS from January 1, 2009 to January 1, 2011. Patients were included if they were 18 of age years or older and received warfarin for at least three days and excluded for indefinite warfarin discontinuation or an indication following orthopedic surgery. A total of 179 patients were included in each group.RESULTS: There was no statistically significant difference in the time required to reach a therapeutic INR; 3.17 vs. 2.65 days (95% confidence interval -0.09-1.13; P = 0.093). However, the pharmacist group resulted in a lower frequency of supratherapeutic INRs and significantly more time within goal range.SETTING: Community teaching hospital.All authors: Chilipko AA, Norwood DKFiscal year: FY2014Digital Object Identifier: Date added to catalog: 2016-07-15
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 24513419 Available 24513419

CONCLUSION: Similar results were observed for pharmacist-managed and physician-managed patients for INR monitoring and outcome rates. However, the pharmacist-managed patients demonstrated a lower incidence of supratherapeutic INRs and significantly more time within goal.

DESIGN: Retrospective cohort study.

INTERVENTIONS: The electronic medical record was reviewed for demographics, warfarin indication and goal range, international normalized ratios (INRs), albumin, drug-drug interactions, bleeding, and thrombotic rates.

MAIN OUTCOME MEASURES: Primary endpoints included mean time to therapeutic INR, mean time within goal, frequency of supratherapeutic INRs, bleeding, thrombotic rates, and mean INR on discharge.

OBJECTIVE: The purpose of this study was to evaluate warfarin management by pharmacists compared with physicians through an inpatient anticoagulation management service (AMS).

PATIENTS, PARTICIPANTS: Patients were randomly selected from the Inpatient AMS from January 1, 2009 to January 1, 2011. Patients were included if they were 18 of age years or older and received warfarin for at least three days and excluded for indefinite warfarin discontinuation or an indication following orthopedic surgery. A total of 179 patients were included in each group.

RESULTS: There was no statistically significant difference in the time required to reach a therapeutic INR; 3.17 vs. 2.65 days (95% confidence interval -0.09-1.13; P = 0.093). However, the pharmacist group resulted in a lower frequency of supratherapeutic INRs and significantly more time within goal range.

SETTING: Community teaching hospital.

English

Powered by Koha